![4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride CAS 106261-49-8 Imatinib Mesylate Intermedju Purità Għolja Dehru Stampa](https://www.ruifuchemical.com/uploads/d1fa2a19.jpg)
4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride CAS 106261-49-8 Imatinib Mesylate Intermedju Purità Għolja
Provvista Kummerċjali Imatinib Mesylate u Intermedji Relatati:
Imatinib Mesylate CAS: 220127-57-1
N-(2-Methyl-5-nitrofenil)-4-(piridin-3-yl)pirimidin-2-amine CAS: 152460-09-8
N-(5-Amino-2-methylphenyl)-4-(3-piridil)-2-pirimidina CAS: 152460-10-1
4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride CAS: 106261-49-8
| Isem Kimiku | 4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride |
| Sinonimi | Imatinib Mesylate Intermedju |
| Numru CAS | 106261-49-8 |
| Numru CAT | RF-PI229 |
| Status tal-istokk | Fil-Ħażna, Skala ta' Produzzjoni Sa Tunnellati |
| Formula Molekulari | C13H20Cl2N2O2 |
| Piż Molekulari | 307.22 |
| Punt tat-tidwib | 305.0~307.0℃ |
| Solubilità | Solubbli fl-Ilma |
| Brand | Ruifu Kimika |
| Oġġett | Speċifikazzjonijiet |
| Dehra | Trab abjad għal Kważi Abjad għal Kristall |
| Purità / Metodu ta 'Analiżi | ≥98.0% (HPLC) |
| Telf fuq Tnixxif | ≤0.50% |
| Residwu mat-tqabbid | ≤0.50% |
| Impuritajiet Totali | ≤2.0% |
| Impurità Unika Massima | ≤1.0% |
| Standard tat-Test | Standard tal-Intrapriża |
| Użu | Intermedju Farmaċewtiku ta' Imatinib Mesylate (CAS: 220127-57-1) |
Pakkett: Flixkun, borża tal-fojl tal-aluminju, tanbur tal-kartun, 25kg/Drum, jew skont il-ħtieġa tal-klijent.
Kundizzjoni tal-Ħżin:Aħżen f'kontenituri ssiġillati f'post frisk u niexef;Ipproteġi mid-dawl, l-umdità u l-infestazzjoni tal-pesti.
Shanghai Ruifu Chemical Co., Ltd hija l-manifattur u l-fornitur ewlieni ta '4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride (CAS: 106261-49-8) bi kwalità għolja.Huwahuwa intermedju tipikament fis-sintesi ta 'Imatinib Mesylate (CAS: 220127-57-1).Imatinib Mesylate huwa inibitur tat-tyrosine kinase, speċifiku ħafna għal BCR-ABL, mediċina orali għat-trattament ta' pazjenti adulti b'lewkimja majelojde kronika pożittiva fil-kromożomi ta' Philadelphia (CML) fil-fażi akuta u ċerti forom ta' lewkimja limfoblastika akuta (ALL), aċċellerata. fażi u fażi kronika wara l-falliment tat-terapija b'interferon.
![4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride CAS 106261-49-8 Imatinib Mesylate Intermedju Purità Għolja](https://www.ruifuchemical.com/uploads/d1fa2a19-300x300.jpg)